Galderma Successfully Issued an Inaugural CHF 500 Million Bond
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
ZUG, Switzerland -- Businesswire -- Galderma Group AG (SWX:GALD):
NOT FOR DISTRIBUTION IN THE UNITED STATES OR IN ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE RESTRICTED BY APPLICABLE LAW OR REGULATION
Galderma successfully placed an inaugural bond with a total amount of CHF 500 million through a dual tranche offering:
· CHF 250 million bond, with a 4-year maturity and a 1.6% fixed-rate annual coupon · CHF 250 million bond, with a 8-year maturity and a 1.9% fixed-rate annual coupon
The payment date of the bonds is September 27, 2024. The bonds will be listed on the SIX Swiss Exchange and are expected to be included in the domestic segment of the Swiss Bond Index (SBI). The bonds were placed under the lead management of UBS and Zürcher Kantonalbank.
To support the issuance of the bond, Galderma obtained two investment grade ratings from UBS and Zürcher Kantonalbank (BBB- “Improving” and BBB- “Stable” respectively).
The net proceeds of the transaction will be used for the partial refinancing of its existing Bank Term Loan issued at Initial Public Offering (IPO) and general purposes. This successful issuance is leverage-neutral and doesn’t affect Galderma’s guidance for full-year 2024 on net sales, Core EBITDA margin, leverage and interest cash expense for the second half of 2024, as last communicated on July 25, 2024.
About Galderma
Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ - the skin - meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com
Disclaimer This announcement does not constitute an offer to sell, a solicitation of an offer to buy any of the bonds described herein or any other securities issued by Galderma, or any kind of advice, nor shall there be any offer, solicitation or sale in any country or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any country or jurisdiction. This press release also does not constitute a prospectus as such term is understood pursuant to the Swiss Financial Services Act and not a prospectus under any other applicable laws. A decision to invest in the bonds mentioned herein should be solely made based on the prospectus published in connection with the offering. Except as required by law, Galderma does not have the intention or obligation to update any part of this publication.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240828094515/en/
이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.
출처:Galderma
보도자료 통신사 뉴스와이어(www.newswire.co.kr) 배포
Copyright © 뉴스와이어. 무단전재 및 재배포 금지.
- 서울 평창동 이엔갤러리, 남재현 작가 ‘Moon Over September’ 개인전 개최 - 뉴스와이어
- SAS코리아, 이중혁 신임 대표이사 선임 - 뉴스와이어
- 항공안전기술원, 드론 실증도시 구축사업으로 지자체별 지역 특성 맞춤형 드론 활용 서비스 지
- 대웅제약, 숙취해소제 ‘에너씨슬 퍼펙트샷 쎈’ 출시 - 뉴스와이어
- LIG넥스원, 이라크와 중거리 지대공 유도무기 ‘천궁II’ 공급계약 체결 - 뉴스와이어
- 한국지역난방공사, 2024년도 신입직원 68명 임용 - 뉴스와이어
- 테바소프트 ‘2024 에듀테크 코리아 페어’ 참가… AI 기반 감정 교육 솔루션 공개 - 뉴스와이어
- 두구다, 중기부 ‘팁스’ 선정… AI 기반 의료 경영 최적화 솔루션 ‘메디버니’ 개발 본격화 -
- GC녹십자, 혈우병 환자 개인맞춤형 소프트웨어 ‘WAPPS-HEMO’ 업그레이드 출시 - 뉴스와이어
- 인천창조경제혁신센터-대한항공, 항공우주산업 분야 오픈이노베이션 사업설명회 개최 - 뉴스와